uniQure Faces Class Action Lawsuit Impacting Stock Price
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy QURE?
Source: PRnewswire
- Class Action Filed: Berger Montague PC has announced a class action lawsuit against uniQure N.V. on behalf of investors who acquired securities between September 24 and October 31, 2025, highlighting significant investor concerns regarding the company's transparency.
- FDA Approval Issues: The complaint alleges that uniQure failed to adequately disclose that the pivotal study design for its AMT-130 drug was not fully approved by the FDA, which could lead to delays in the Biologics License Application (BLA) timeline, thereby impacting future revenue expectations.
- Stock Price Plunge: On November 3, 2025, uniQure's stock plummeted over 49%, from $67.69 on October 31 to $34.29, following the FDA's rejection of its Phase I/II data as primary evidence for BLA submission, reflecting a pessimistic market sentiment regarding the company's future prospects.
- Investor Rights Reminder: Investors must seek to be appointed as lead plaintiff representatives by April 13, 2026, indicating a heightened focus on corporate governance and disclosure practices, which may influence future investment decisions and market confidence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 23.430
Low
33.00
Averages
49.88
High
70.00
Current: 23.430
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Berger Montague PC has announced a class action lawsuit against uniQure N.V. on behalf of investors who acquired securities between September 24 and October 31, 2025, highlighting significant investor concerns regarding the company's transparency.
- FDA Approval Issues: The complaint alleges that uniQure failed to adequately disclose that the pivotal study design for its AMT-130 drug was not fully approved by the FDA, which could lead to delays in the Biologics License Application (BLA) timeline, thereby impacting future revenue expectations.
- Stock Price Plunge: On November 3, 2025, uniQure's stock plummeted over 49%, from $67.69 on October 31 to $34.29, following the FDA's rejection of its Phase I/II data as primary evidence for BLA submission, reflecting a pessimistic market sentiment regarding the company's future prospects.
- Investor Rights Reminder: Investors must seek to be appointed as lead plaintiff representatives by April 13, 2026, indicating a heightened focus on corporate governance and disclosure practices, which may influence future investment decisions and market confidence.
See More
Class Action Lawsuit Announced for uniQure N.V.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased uniQure N.V. shares between September 24 and October 31, 2025, allowing potential lead plaintiffs to apply by April 13, 2026, highlighting investor concerns over potential losses.
- Compensation Mechanism: Investors joining the lawsuit will incur no upfront costs, as the law firm operates on a contingency fee basis, thereby reducing financial barriers for affected investors and encouraging broader participation.
- Lawsuit Background: The lawsuit alleges that uniQure failed to adequately disclose that its pivotal study design for a key drug candidate was not fully approved by the FDA and that delays in its Biologics License Application timeline were likely, undermining investor confidence in the company's prospects.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Notice of Class Action Lawsuit Against uniQure N.V.
- Class Action Initiation: Rosen Law Firm reminds investors who purchased ordinary shares of uniQure N.V. between September 24 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that uniQure misrepresented key aspects of its leading drug candidate's pivotal study, including that it was not fully approved by the FDA, resulting in investor losses when the true details emerged, which could impact the company's reputation and future financing capabilities.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its successful track record, thus investors should carefully select experienced legal counsel.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on how to participate in the lawsuit, ensuring they have appropriate legal representation in the class action.
See More
uniQure Faces Class Action Lawsuit Warning
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against uniQure N.V. for violations of securities laws, concerning securities transactions from September 24 to October 31, 2025, potentially impacting investor rights.
- False Statement Allegations: The complaint alleges that uniQure made false and misleading statements to the market, failing to secure full FDA approval for its pivotal study, thereby misleading investors about the timeline for its Biologics License Application.
- Investor Losses: As the market learned the truth about uniQure, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to contact them before April 13, 2026, to participate in the lawsuit.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations and urges shareholders to take action before class certification to ensure their rights are protected.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. (NASDAQ:QURE) has been named in a class action lawsuit for securities fraud, alleging significant misstatements and omissions regarding its Huntington's disease gene therapy during the period from September 24 to October 31, 2025, potentially leading to substantial investor losses.
- Key Allegations: The lawsuit claims that uniQure failed to adequately disclose that the design of its AMT-130 clinical trial was not fully approved by the FDA and exaggerated the results of the Pivotal Study, which misled investors about the company's prospects and affected stock price stability.
- Investor Action: Affected investors are urged to apply for lead plaintiff status by April 13, 2026, to represent other investors in the lawsuit, with Kessler Topaz Meltzer & Check, LLP offering free consultations to encourage proactive measures to protect their rights.
- Law Firm Overview: Kessler Topaz Meltzer & Check, LLP is a leading U.S. law firm specializing in securities fraud class actions, having successfully represented major investors in securing significant recoveries in securities litigation, demonstrating its expertise in investor protection.
See More
uniQure Investors Encouraged to Seek Legal Options for Losses
- Claim Opportunity: Faruqi & Faruqi LLP is investigating potential claims against uniQure N.V., specifically targeting investors who suffered losses exceeding $50,000 between September 24, 2025, and October 31, 2025, urging them to contact the firm to discuss their legal rights.
- Legal Consultation: Investors can directly reach out to attorney Josh Wilson by calling 877-247-4292 or 212-983-9330 (Ext. 1310) for detailed information on the claims process, ensuring their rights are protected.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against uniQure is April 13, 2026, necessitating prompt action from affected investors.
- Law Firm Background: Faruqi & Faruqi is a leading national securities law firm focused on providing legal support to investors, helping them navigate losses and risks in the securities market.
See More
uniQure Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Berger Montague PC has announced a class action lawsuit against uniQure N.V. on behalf of investors who acquired securities between September 24 and October 31, 2025, highlighting significant investor concerns regarding the company's transparency.
- FDA Approval Issues: The complaint alleges that uniQure failed to adequately disclose that the pivotal study design for its AMT-130 drug was not fully approved by the FDA, which could lead to delays in the Biologics License Application (BLA) timeline, thereby impacting future revenue expectations.
- Stock Price Plunge: On November 3, 2025, uniQure's stock plummeted over 49%, from $67.69 on October 31 to $34.29, following the FDA's rejection of its Phase I/II data as primary evidence for BLA submission, reflecting a pessimistic market sentiment regarding the company's future prospects.
- Investor Rights Reminder: Investors must seek to be appointed as lead plaintiff representatives by April 13, 2026, indicating a heightened focus on corporate governance and disclosure practices, which may influence future investment decisions and market confidence.
See More
Class Action Lawsuit Announced for uniQure N.V.
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased uniQure N.V. shares between September 24 and October 31, 2025, allowing potential lead plaintiffs to apply by April 13, 2026, highlighting investor concerns over potential losses.
- Compensation Mechanism: Investors joining the lawsuit will incur no upfront costs, as the law firm operates on a contingency fee basis, thereby reducing financial barriers for affected investors and encouraging broader participation.
- Lawsuit Background: The lawsuit alleges that uniQure failed to adequately disclose that its pivotal study design for a key drug candidate was not fully approved by the FDA and that delays in its Biologics License Application timeline were likely, undermining investor confidence in the company's prospects.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
Notice of Class Action Lawsuit Against uniQure N.V.
- Class Action Initiation: Rosen Law Firm reminds investors who purchased ordinary shares of uniQure N.V. between September 24 and October 31, 2025, to apply as lead plaintiffs by April 13, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that uniQure misrepresented key aspects of its leading drug candidate's pivotal study, including that it was not fully approved by the FDA, resulting in investor losses when the true details emerged, which could impact the company's reputation and future financing capabilities.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, highlighting its successful track record, thus investors should carefully select experienced legal counsel.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm website or call the toll-free number for more information on how to participate in the lawsuit, ensuring they have appropriate legal representation in the class action.
See More
uniQure Faces Class Action Lawsuit Warning
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against uniQure N.V. for violations of securities laws, concerning securities transactions from September 24 to October 31, 2025, potentially impacting investor rights.
- False Statement Allegations: The complaint alleges that uniQure made false and misleading statements to the market, failing to secure full FDA approval for its pivotal study, thereby misleading investors about the timeline for its Biologics License Application.
- Investor Losses: As the market learned the truth about uniQure, investors suffered damages, prompting the Schall Law Firm to encourage affected shareholders to contact them before April 13, 2026, to participate in the lawsuit.
- Legal Consultation Opportunity: The Schall Law Firm offers free legal consultations and urges shareholders to take action before class certification to ensure their rights are protected.
See More
uniQure Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: uniQure N.V. (NASDAQ:QURE) has been named in a class action lawsuit for securities fraud, alleging significant misstatements and omissions regarding its Huntington's disease gene therapy during the period from September 24 to October 31, 2025, potentially leading to substantial investor losses.
- Key Allegations: The lawsuit claims that uniQure failed to adequately disclose that the design of its AMT-130 clinical trial was not fully approved by the FDA and exaggerated the results of the Pivotal Study, which misled investors about the company's prospects and affected stock price stability.
- Investor Action: Affected investors are urged to apply for lead plaintiff status by April 13, 2026, to represent other investors in the lawsuit, with Kessler Topaz Meltzer & Check, LLP offering free consultations to encourage proactive measures to protect their rights.
- Law Firm Overview: Kessler Topaz Meltzer & Check, LLP is a leading U.S. law firm specializing in securities fraud class actions, having successfully represented major investors in securing significant recoveries in securities litigation, demonstrating its expertise in investor protection.
See More
uniQure Investors Encouraged to Seek Legal Options for Losses
- Claim Opportunity: Faruqi & Faruqi LLP is investigating potential claims against uniQure N.V., specifically targeting investors who suffered losses exceeding $50,000 between September 24, 2025, and October 31, 2025, urging them to contact the firm to discuss their legal rights.
- Legal Consultation: Investors can directly reach out to attorney Josh Wilson by calling 877-247-4292 or 212-983-9330 (Ext. 1310) for detailed information on the claims process, ensuring their rights are protected.
- Class Action Deadline: The firm reminds investors that the deadline to seek the role of lead plaintiff in the federal securities class action against uniQure is April 13, 2026, necessitating prompt action from affected investors.
- Law Firm Background: Faruqi & Faruqi is a leading national securities law firm focused on providing legal support to investors, helping them navigate losses and risks in the securities market.
See More
